Data on Immunovia’s PancreaSure test to be presented in Presidential Plenary at CGA-IGC 2026 Annual Meeting
Data on Immunovia’s PancreaSure test to be presented in Presidential Plenary at CGA-IGC 2026 Annual Meeting
Immunovia AB (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, today announced that an analysis of the accuracy of the PancreaSure® test in individuals at hereditary and familial risk of pancreatic cancer has been selected for oral presentation during a Presidential Plenary session at the 30th Annual Meeting of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) in Denver, Colorado. The data will be presented on November 3, 2026, by Dr. Tamas Gonda, New York University, lead author of the study.
The CGA-IGC Annual Meeting is the leading scientific meeting in the Americas on inherited gastrointestinal cancer. It brings together clinicians, genetic counselors and researchers who manage surveillance for individuals at inherited risk of pancreatic cancer, the intended use population for PancreaSure.
“We are grateful to Dr. Gonda and his co-authors for bringing this work to CGA-IGC. This is a clinical community whose judgment matters greatly to us. We hope the presentation adds to the discussion on how blood-based testing can foster early detection for individuals at inherited risk of pancreatic cancer,” says Jeff Borcherding, CEO and President, Immunovia.
Presentation details
“A Validated and Clinically Available Serum Biomarker Test for Early Detection of Pancreatic Cancer Demonstrates Robust Performance Across Independent High-Risk Genetic and Familial Surveillance Cohorts” will be presented during the Presidential Plenary II on November 3 (1:45-2:00 PM, MT). The presentation will be given by the study’s lead author, Dr. Tamas Gonda, Director, Pancreas Disease Program, NYU Grossman School of Medicine.
The full article
Gonda T, et al. The PancreaSure multianalyte blood test performs well at distinguishing early-stage pancreatic ductal adenocarcinoma from high-risk controls: a retrospective secondary analysis. J Clin Med. 2026;15(19):7355. doi:10.3390/jcm15197355
For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com